Aziz Sawaf named Vir Executive VP & CFO, Brent Sabatini returns to SVP & Chief Accounting Officer

Vir Biotechnology, Inc. (VIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results – Phase 2 SOLSTICE data presented at the EASL Congress showed that elebsiran and tobevibart achieved undetectable HDV RNA in 88% of participants with chronic hepatitis delta

Vir Biotechnology shares (NASDAQ:VIR) fell 5.6% after CFO Jason O’Byrne announced his departure. The company appointed Brent Sabatini, Senior VP and Chief Accounting Officer, as interim principal financial officer effective July 23, with O’Byrne staying through Aug. 3. Vir said it will search for a new CFO.

Synopsys Inc (SNPS) rose 10.59% to $480.98 on Oct 1, driven by a $1B+ AWS deal, OpenAI partnership, and raised FY2027 guidance. Call options volume was 4.5x puts. Analysts raised price targets to $620 (Rosenblatt) and $570 (StoneX). 3-month implied volatility fell 0.89% to 46.22%.

BMO Capital reiterated an Outperform rating on Eli Lilly (LLY) with a $1,400 price target, citing strong TRIUMPH-2 data for Reta. The company's stock has surged 41% over the past year, with revenue up nearly 50%. Recent FDA approvals for Onswik and Inluriyo, along with positive analyst outlooks, underscore Eli Lilly's growth prospects.

McKesson (MCK) shares rose 4.4% after extending its pharmaceutical distribution agreement with CVS Health to 2032. The company reaffirmed its FY2027 EPS guidance of $44.20-$45.00 and long-term EPS growth target of 13-16%. Details will be discussed in its Q2 FY2027 earnings call.

Rocket Lab (RKLB) shares rose 4% after securing a 20-launch deal with Synspective, expanding its pipeline to 2031. The agreement covers launches of Synspective's StriX satellites from New Zealand. Synspective's total missions with Rocket Lab now reach 47, making it the largest customer. Rocket Lab's overall backlog exceeds 100 missions.